BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo

Cancer Research
Ching-Chuan KuoJang-Yang Chang

Abstract

BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. BPR0L075 inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC(50) values in single-digit nanomolar ranges. As determined by flow cytometry, human cervical carcinoma KB cells are arrested in G(2)-M phases in a time-dependent manner before cell death occurs. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway. Additional studies indicate that the effect of BPR0L075 on cell cycle arrest is associated with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C. The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis. Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colc...Continue Reading

References

May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·F M DavisP N Rao
Jun 1, 1995·Journal of Cellular Biochemistry·K L King, J A Cidlowski
May 12, 1995·Journal of Medicinal Chemistry·G R PettitF Hogan
Sep 1, 1996·The Journal of Experimental Medicine·P MarchettiG Kroemer
Aug 15, 1997·The Biochemical Journal·G M Cohen
Jan 13, 1998·Current Opinion in Cell Biology·P K SorgerA A Hyman
Jul 17, 1998·Medicinal Research Reviews·A JordanA T McGown
Nov 7, 1998·The Journal of Biological Chemistry·C D ScatenaJ A Pietenpol
Nov 20, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·R L Margolis, L Wilson
Jan 20, 1999·The Journal of Experimental Medicine·S A SusinG Kroemer
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Dumontet, B I Sikic
Sep 29, 1999·Cancer Chemotherapy and Pharmacology·L G WangD R Budman
Apr 8, 2000·Current Opinion in Structural Biology·L A Amos
Apr 11, 2001·Bioorganic & Medicinal Chemistry Letters·S L GwaltneyH L Sham
Mar 22, 2002·The Lancet Oncology·J GriggsR Hesketh
May 31, 2002·Journal of Medicinal Chemistry·Jing-Ping LiouHsing-Pang Hsieh
Jul 23, 2003·Current Medicinal Chemistry·Nguyen-Hai Nam

❮ Previous
Next ❯

Citations

Jul 21, 2012·Pharmaceutical Research·Yan LuDuane D Miller
Oct 11, 2013·Journal of Medicinal Chemistry·Hsueh-Yun LeeJing-Ping Liou
Mar 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shun-Fu ChangJeng-Jiann Chiu
Oct 13, 2006·Biological Procedures Online·Matthew P BadtkeJohn E Tavis
Jul 12, 2011·The Oncologist·Ishwaria M SubbiahApostolia M Tsimberidou
Nov 20, 2012·Future Medicinal Chemistry·Shivaputra A PatilDuane D Miller
Mar 25, 2014·European Journal of Medicinal Chemistry·Chih-Yi ChangJing-Ping Liou
Apr 6, 2012·Expert Opinion on Therapeutic Patents·Christos KontogiorgisDimitra Hadjipavlou-Litina
Dec 10, 2013·Expert Opinion on Therapeutic Patents·Yi-Min LiuJing-Ping Liou
May 20, 2011·Expert Opinion on Therapeutic Patents·Chun Hei Antonio CheungHsing-Pang Hsieh
Mar 5, 2013·Cancer Treatment Reviews·Mohane Selvaraj CoumarChun Hei Antonio Cheung
Nov 28, 2012·Critical Reviews in Oncology/hematology·Céline ClémensonEric Deutsch
Jun 12, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Meihua SuiWeimin Fan
Apr 29, 2016·Journal of Asian Natural Products Research·Chuan ChenDu-Qiang Luo
Oct 26, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Gayong ShimYu-Kyoung Oh
Apr 11, 2009·Oral Oncology·Yuan-Wu ChenHuey-Kang Sytwu
Oct 13, 2015·European Journal of Medicinal Chemistry·Chih-Wei FuWen-Shan Li
Oct 22, 2011·International Journal of Cancer. Journal International Du Cancer·Sin-Ming HuangYi-Ching Wang
Jun 9, 2005·Current Opinion in Chemical Biology·Michelle Arkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis